Compare Adaptive Biotechnologies Corp (ADPT) vs Google Inc (GOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Google Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Google Inc trades at $355.59 (market cap $4.46T). The key difference: Google Inc is far larger — about 1339.3× Adaptive Biotechnologies Corp's market cap, and Google Inc pays a 0.24% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GOOG | |
|---|---|---|
Market Cap | $3.33B | $4.46T |
Sector | Health | Technology |
52-Week High | $22.37 | $399.06 |
52-Week Low | $10.24 | $175.16 |
Enterprise Value | $3.19B | $4.42T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GOOG trades at $363.62, up 2.09% today, reflecting strong momentum after consecutive earnings beats. The stock shows a bullish technical trend with support at $358 and resistance at $369. Revenue grew to $402.84B in 2025, with net income reaching $132.17B, driven by robust profitability margins. Recent news highlights Google's AI advancements and a dividend payment, reinforcing investor confidence.
Outlook remains positive with a consensus price target of $457.50, indicating 26% upside. Risks include competitive pressures in AI and regulatory scrutiny. Analyst sentiment is overwhelmingly bullish (86.84% buy ratings), supported by strong cash flow growth and strategic investments in fusion technology and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
